

Supporting Information for

ORIGINAL ARTICLE

Pure redox-sensitive paclitaxel–maleimide prodrug nanoparticles: Endogenous albumin-induced size switching and improved antitumor efficiency

Xinyu Lou^{a,†}, Dong Zhang^{b,c,†}, Hao Ling^b, Zhonggui He^b, Jin Sun^b, Mengchi Sun^{b,*}, Dongchun Liu^{a,*}

^a*School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China*

^b*Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China*

^c*Jiangsu Hengrui Medicine Co., Ltd., Lianyungang Eco & Tech Development Zone, Lianyungang 222047, China*

Received 25 August 2020; received in revised form 29 October 2020; accepted 18 November 2020

[†]These authors made equal contributions to this work.

*Corresponding authors. Tel./fax: +86 24 23984318 (Dongchun Liu); +86 24 23986321 (Mengchi Sun).

E-mail addresses: liudongchun@outlook.com (Dongchun Liu), smc_1990@aliyun.com (Mengchi Sun).

Running title: Pure redox-sensitive paclitaxel-maleimide prodrug nanoparticles




Figure S1 The long-term stability of nanoparticles within 10 days at 4 °C.




Figure S2 The particle sizes of PTX-maleimide prodrug NPs exposure to the albumin solution.




Figure S3 Maleimide groups on NPs.




Figure S4 (A) Pharmacokinetic profiles of NPs after injection (Taxol, PMAL and PSSMAL) at an equivalent PTX dose of 4 mg/kg, multiple organs and tumor biodistribution of PTX at 6 (B) and 24 h (C) in 4T1 xenograft tumor-bearing BALB/c mice; $n = 3$, $*P < 0.05$, $**P < 0.01$, $***P < 0.001$.